Seyed Ahmadi, Shilan http://orcid.org/0000-0001-6970-2877
Pivodic, Aldina
Svensson, Ann-Marie
Wedel, Hans
Rathsman, Björn
Nyström, Thomas
Ludvigsson, Johnny
Lind, Marcus
Funding for this research was provided by:
Novo Nordisk Fonden
Swedish government
University of Gothenburg
Article History
Received: 21 September 2021
Accepted: 19 December 2021
First Online: 24 February 2022
Declarations
:
: TN has received honoraria on expert group participation from AstraZeneca, Merck Shark & Dohme, Novo Nordisk, Eli Lilly and Company, Boerhinger Ingelheim, Abbot and Amgen. ML has received grants from Eli Lilly and Novo Nordisk, and consulting fees from AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, MSD and Novo Nordisk. SSA, AP, AS, HW, BR, JL: no conflicts of interests.
: Each patient provides informed consent for inclusion in the NDR.
: Not required.
: This study was approved by the regional ethical and review board of the University of Gothenburg, Gothenburg, Sweden (Dnr 977–17).